TickerFacts.

Anbio Biotechnology (NNNN): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$6.74M
Year ended 2025-12-31
$4.45M2022-12-31: $4.45M2023-12-31: $898.4K2024-12-31: $2.08M2025-12-31: -$6.74M-$6.74M
2022-12-31 Operating Cash Flow (USD) 2025-12-31
Period endedOperating Cash FlowChange YoYSource filing
2025-12-31-$6.74Mn/m2026-04-07, From 2025-01-01
2024-12-31$2.08M+131.6%2026-04-07, From 2024-01-01
2023-12-31$898.4K-79.8%2026-04-07, From 2023-01-01
2022-12-31$4.45Mn/a2025-04-28, From 2022-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating Cash FlowChange YoY
Anbio Biotechnology (NNNN)2025-12-31-$6.74Mn/m
Aspira Women's Health Inc. (AWHL)2025-12-31-$7.03Mn/m
Biomerica Inc (BMRA)2026-05-31-$3.42Mn/m
Insight Molecular Diagnostics Inc. (IMDX)2025-12-31-$22.18Mn/m
Immucell Corp (ICCC)2025-12-31$2.48M+591.6%
Alpha Teknova, Inc. (TKNO)2025-12-31-$8.65Mn/m
Volitionrx Ltd (VNRX)2025-12-31-$19.68Mn/m
Celldex Therapeutics, Inc. (CLDX)2025-12-31-$210.94Mn/m
Intellia Therapeutics, Inc. (NTLA)2025-12-31-$394.74Mn/m

Compare NNNN, AWHL, BMRA, IMDX side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗